The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Ruxolitinib plus carfilzomib & dexamethasone for patients with carfilzomib-refractory myeloma
Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, shares some insights into the CARJAK trial (NCT03773107), which evaluated the safety and efficacy of ruxolitinib in combination with carfilzomib and dexamethasone in patients with carfilzomib-refractory multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
